<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7358098\results\search\disease\results.xml">
  <result pre="On the use of immune checkpoint inhibitors in patients with" exact="viral" post="infections including COVID-19 http://orcid.org/0000-0001-7862-3695GambichlerThilo1ReutherJudith1ScheelChristina H12http://orcid.org/0000-0001-9183-653XBeckerJÃ¼rgen Christian34[1], Skin Cancer Center,"/>
  <result pre="the use of immune checkpoint inhibitors in patients with viral" exact="infections" post="including COVID-19 http://orcid.org/0000-0001-7862-3695GambichlerThilo1ReutherJudith1ScheelChristina H12http://orcid.org/0000-0001-9183-653XBeckerJÃ¼rgen Christian34[1], Skin Cancer Center, Department"/>
  <result pre="in patients with viral infections including COVID-19 http://orcid.org/0000-0001-7862-3695GambichlerThilo1ReutherJudith1ScheelChristina H12http://orcid.org/0000-0001-9183-653XBeckerJÃ¼rgen Christian34[1]," exact="Skin Cancer" post="Center, Department of DermatologyRuhr-Universitat BochumBochumGermany[2], Institute of Stem Cell"/>
  <result pre="patients with viral infections including COVID-19 http://orcid.org/0000-0001-7862-3695GambichlerThilo1ReutherJudith1ScheelChristina H12http://orcid.org/0000-0001-9183-653XBeckerJÃ¼rgen Christian34[1], Skin" exact="Cancer" post="Center, Department of DermatologyRuhr-Universitat BochumBochumGermany[2], Institute of Stem Cell"/>
  <result pre="DermatologyRuhr-Universitat BochumBochumGermany[2], Institute of Stem Cell ResearchHelmholtz Center MunichNeuherbergGermany[3], Translational" exact="Skin Cancer" post="Research, German Cancer Consortium (DKTK), DermatologyUniversity Duisburg-EssenEssenGermany[4], German Cancer"/>
  <result pre="BochumBochumGermany[2], Institute of Stem Cell ResearchHelmholtz Center MunichNeuherbergGermany[3], Translational Skin" exact="Cancer" post="Research, German Cancer Consortium (DKTK), DermatologyUniversity Duisburg-EssenEssenGermany[4], German Cancer"/>
  <result pre="Stem Cell ResearchHelmholtz Center MunichNeuherbergGermany[3], Translational Skin Cancer Research, German" exact="Cancer" post="Consortium (DKTK), DermatologyUniversity Duisburg-EssenEssenGermany[4], German Cancer Research Center (DKFZ)HeidelbergGermany"/>
  <result pre="Skin Cancer Research, German Cancer Consortium (DKTK), DermatologyUniversity Duisburg-EssenEssenGermany[4], German" exact="Cancer" post="Research Center (DKFZ)HeidelbergGermany Correspondence to Professor Thilo Gambichler; t.gambichler@klinikum-bochum.de"/>
  <result pre="controversies regarding the use of immune checkpoint inhibitors (ICIs) in" exact="cancer" post="patients with viral infections, including AIDS, hepatitis B and"/>
  <result pre="use of immune checkpoint inhibitors (ICIs) in cancer patients with" exact="viral" post="infections, including AIDS, hepatitis B and C, progressive multifocal"/>
  <result pre="inhibitors (ICIs) in cancer patients with viral infections, including AIDS," exact="hepatitis" post="B and C, progressive multifocal leukoencephalopathy, influenza, and COVID-19."/>
  <result pre="patients with viral infections, including AIDS, hepatitis B and C," exact="progressive multifocal leukoencephalopathy," post="influenza, and COVID-19. In detail, we provide available information"/>
  <result pre="used to treat ICI-related adverse events affect the risk of" exact="infection" post="or virulence of pre-existing infections, (4) whether the use"/>
  <result pre="that even qualify them as a therapeutic approach for these" exact="viral" post="infections. immune evation tumor escape T-lymphocytes vaccination review Introduction"/>
  <result pre="as a therapeutic approach for these viral infections. immune evation" exact="tumor" post="escape T-lymphocytes vaccination review Introduction Cancer cells may escape"/>
  <result pre="viral infections. immune evation tumor escape T-lymphocytes vaccination review Introduction" exact="Cancer" post="cells may escape immune surveillance through a variety of"/>
  <result pre="immune checkpoint pathways that serve to suppress immune responses against" exact="tumor" post="cells. Immune checkpoint inhibitors (ICI) boost antitumor immune responses"/>
  <result pre="by interrupting coinhibitory signaling pathways to promote immune-mediated killing of" exact="tumor" post="cells. The introduction of ICI in 2011 for therapy"/>
  <result pre="management of many solid cancers and hematological malignancies (eg, melanoma," exact="Merkel cell carcinoma," post="squamous cell carcinomas, colorectal cancer, renal cell carcinoma, urothelial"/>
  <result pre="solid cancers and hematological malignancies (eg, melanoma, Merkel cell carcinoma," exact="squamous cell" post="carcinomas, colorectal cancer, renal cell carcinoma, urothelial cancer, Hodgkin"/>
  <result pre="hematological malignancies (eg, melanoma, Merkel cell carcinoma, squamous cell carcinomas," exact="colorectal cancer," post="renal cell carcinoma, urothelial cancer, Hodgkin lymphoma).1â€&quot;3 Currently, antibodies"/>
  <result pre="(eg, melanoma, Merkel cell carcinoma, squamous cell carcinomas, colorectal cancer," exact="renal cell carcinoma," post="urothelial cancer, Hodgkin lymphoma).1â€&quot;3 Currently, antibodies targeting three different"/>
  <result pre="PD-1 plays an important role in limiting immune responses in" exact="peripheral" post="tissues. The interaction of PD-1 with its ligands (PD-L1/2)"/>
  <result pre="cells, and Tregs. PDâ€�L1 is expressed on several cells, including" exact="tumor" post="cells and some host cells such as myeloid, lymphoid"/>
  <result pre="cells and some host cells such as myeloid, lymphoid and" exact="epithelial" post="cells. The interaction between PDâ€�1 and PDâ€�L1 blocks CD8+"/>
  <result pre="differentiation of CD4+ T lymphocytes into Tregs.1 5 6 Most" exact="cancer" post="cells possess the ability to express inhibitory ligands such"/>
  <result pre="in immune escape. Hence, ICI do not result in killing" exact="tumor" post="cells directly but enhance or restore immune responses and"/>
  <result pre="important factor contributing to weakened T cell activity against both" exact="cancer" post="and infectious agents. Notably, T cell exhaustion is a"/>
  <result pre="contributing to weakened T cell activity against both cancer and" exact="infectious" post="agents. Notably, T cell exhaustion is a distinguishing feature"/>
  <result pre="Notably, T cell exhaustion is a distinguishing feature of many" exact="chronic" post="viral infections such as HIV and hepatitis B virus"/>
  <result pre="T cell exhaustion is a distinguishing feature of many chronic" exact="viral" post="infections such as HIV and hepatitis B virus (HBV)"/>
  <result pre="cell exhaustion is a distinguishing feature of many chronic viral" exact="infections" post="such as HIV and hepatitis B virus (HBV) infection."/>
  <result pre="feature of many chronic viral infections such as HIV and" exact="hepatitis" post="B virus (HBV) infection. Indeed, T cell exhaustion was"/>
  <result pre="T cell exhaustion was first described in the context of" exact="chronic" post="infections.7 8 In the following, T lymphocytes with a"/>
  <result pre="lymphocytes with a similar phenotype were also detected in the" exact="tumor" post="microenvironment.2 7â€&quot;9 Exhausted T lymphocytes are functionally characterized by"/>
  <result pre="a characteristic. Given the similarities between the immune response to" exact="cancer" post="and chronic infections, one may hypothesize that the use"/>
  <result pre="Given the similarities between the immune response to cancer and" exact="chronic" post="infections, one may hypothesize that the use of ICI"/>
  <result pre="that the use of ICI should not be harmful for" exact="tumor" post="patients with infections or may even provide a benefit."/>
  <result pre="of ICI should not be harmful for tumor patients with" exact="infections" post="or may even provide a benefit. However, as of"/>
  <result pre="or may even provide a benefit. However, as of yet," exact="tumor" post="patients with existing viral infections are excluded from participation"/>
  <result pre="a benefit. However, as of yet, tumor patients with existing" exact="viral" post="infections are excluded from participation in many treatment protocols"/>
  <result pre="benefit. However, as of yet, tumor patients with existing viral" exact="infections" post="are excluded from participation in many treatment protocols for"/>
  <result pre="in many treatment protocols for ICI.7 8 With respect to" exact="acquired" post="infectious diseases during ICI treatment, no increased risk was"/>
  <result pre="many treatment protocols for ICI.7 8 With respect to acquired" exact="infectious diseases" post="during ICI treatment, no increased risk was observed in"/>
  <result pre="These are summarized as immuneâ€�related adverse events (irAEs) and include" exact="autoimmune" post="colitis, pneumonitis, hypophysitis, hepatitis, thyroiditis and so on.10â€&quot;12 Since"/>
  <result pre="adverse events (irAEs) and include autoimmune colitis, pneumonitis, hypophysitis, hepatitis," exact="thyroiditis" post="and so on.10â€&quot;12 Since irAEs may require immunosuppressive therapy,"/>
  <result pre="Since irAEs may require immunosuppressive therapy, including high-dose corticosteroids and/or" exact="tumor" post="necrosis factor (TNF)-Î± blockers, the risk of infection or"/>
  <result pre="corticosteroids and/or tumor necrosis factor (TNF)-Î± blockers, the risk of" exact="infection" post="or reactivation of chronic or latent viral infections (eg,"/>
  <result pre="factor (TNF)-Î± blockers, the risk of infection or reactivation of" exact="chronic" post="or latent viral infections (eg, HBV or hepatitis C"/>
  <result pre="the risk of infection or reactivation of chronic or latent" exact="viral" post="infections (eg, HBV or hepatitis C virus (HCV)) may"/>
  <result pre="risk of infection or reactivation of chronic or latent viral" exact="infections" post="(eg, HBV or hepatitis C virus (HCV)) may be"/>
  <result pre="reactivation of chronic or latent viral infections (eg, HBV or" exact="hepatitis C" post="virus (HCV)) may be secondarily increased.10â€&quot;12 In this respect,"/>
  <result pre="also be noted that much of the morbidity of persistent" exact="viral" post="diseases is caused by collateral damage caused by the"/>
  <result pre="viral diseases is caused by collateral damage caused by the" exact="chronic" post="reactive inflammation associated with the inability of viral clearance;"/>
  <result pre="by the chronic reactive inflammation associated with the inability of" exact="viral" post="clearance; both may be boosted by ICI therapy. In"/>
  <result pre="the pros and cons of using ICI in patients with" exact="viral" post="infections including COVID-19. HIV infection Antiretroviral therapy has significantly"/>
  <result pre="pros and cons of using ICI in patients with viral" exact="infections" post="including COVID-19. HIV infection Antiretroviral therapy has significantly decreased"/>
  <result pre="of using ICI in patients with viral infections including COVID-19." exact="HIV infection" post="Antiretroviral therapy has significantly decreased the incidence of AIDS"/>
  <result pre="using ICI in patients with viral infections including COVID-19. HIV" exact="infection" post="Antiretroviral therapy has significantly decreased the incidence of AIDS"/>
  <result pre="decreased the incidence of AIDS and thus the mortality of" exact="HIV infection." post="However, complete eradication of HIV with antiviral agents has"/>
  <result pre="of AIDS and thus the mortality of HIV infection. However," exact="complete" post="eradication of HIV with antiviral agents has not yet"/>
  <result pre="resting memory CD4+ lymphocytes carrying an integrated form of the" exact="viral" post="genome that lacks the ability to produce viral proteins.13"/>
  <result pre="of the viral genome that lacks the ability to produce" exact="viral" post="proteins.13 In HIV-infected subjects receiving highly active antiretroviral therapy"/>
  <result pre="expression on CD4+ andâ€‰CD8+ lymphocytes appears to strongly correlate with" exact="disease" post="outcome. Specifically, in untreated patients with HIV, high PD-1"/>
  <result pre="correlate with a decrease in CD4+ T lymphocytes during both" exact="acute" post="and chronic infection.7 8 15 Similar to PD-1 upregulation,"/>
  <result pre="a decrease in CD4+ T lymphocytes during both acute and" exact="chronic" post="infection.7 8 15 Similar to PD-1 upregulation, overexpression of"/>
  <result pre="to develop cancer.19 20 In this context, initial observations on" exact="HIV-positive" post="cancer patients treated with ICI are emerging. In a"/>
  <result pre="develop cancer.19 20 In this context, initial observations on HIV-positive" exact="cancer" post="patients treated with ICI are emerging. In a systematic"/>
  <result pre="was the most frequently employed regimen (n=62).19 In this cohort," exact="grade III" post="or higher irAEs were observed in 8.6% of patients."/>
  <result pre="the previous studies reported the occurrence of immune reactivation inflammatory" exact="syndrome" post="during ICI therapy.19 Similar to the safety profile, efficacy"/>
  <result pre="ICI was favorable with an objective response of 63% in" exact="Kaposi sarcoma," post="30% in non-small cell lung carcinoma, and 27% in"/>
  <result pre="an objective response of 63% in Kaposi sarcoma, 30% in" exact="non-small cell lung carcinoma," post="and 27% in melanoma.19 Prompted by these encouraging results,"/>
  <result pre="response of 63% in Kaposi sarcoma, 30% in non-small cell" exact="lung carcinoma," post="and 27% in melanoma.19 Prompted by these encouraging results,"/>
  <result pre="currently conducted.21 22 Accordingly, a task force formed by the" exact="American" post="Society of Clinical Oncology (ASCO) recently recommended the inclusion"/>
  <result pre="tolerability and pharmacokinetics of CTLA-4 inhibition (ipilimumab) in patients with" exact="chronic" post="HIV infection in the absence of concurrent malignancies were"/>
  <result pre="and pharmacokinetics of CTLA-4 inhibition (ipilimumab) in patients with chronic" exact="HIV infection" post="in the absence of concurrent malignancies were recently reported.24"/>
  <result pre="pharmacokinetics of CTLA-4 inhibition (ipilimumab) in patients with chronic HIV" exact="infection" post="in the absence of concurrent malignancies were recently reported.24"/>
  <result pre="inhibition (ipilimumab) in patients with chronic HIV infection in the" exact="absence of" post="concurrent malignancies were recently reported.24 Although only based on"/>
  <result pre="concurrent malignancies were recently reported.24 Although only based on a" exact="limited" post="number of patients (n=24), this study did not reveal"/>
  <result pre="palsy received medium dose prednisone; still, no worsening of his" exact="HIV infection" post="was observed.24 Furthermore, in a randomized, double-blind, placebo-controlled, phase"/>
  <result pre="received medium dose prednisone; still, no worsening of his HIV" exact="infection" post="was observed.24 Furthermore, in a randomized, double-blind, placebo-controlled, phase"/>
  <result pre="testing PD-1 inhibition (nivolumab) in HAART-treated HIV-infected adults without concurrent" exact="cancer" post="(n=8), even a single, low-dose infusion appeared to enhance"/>
  <result pre="including ICI and cytokines will be required to accomplish such" exact="complete" post="remissions.28 Hepatitis B and C Viral caused hepatitis is"/>
  <result pre="and cytokines will be required to accomplish such complete remissions.28" exact="Hepatitis" post="B and C Viral caused hepatitis is one of"/>
  <result pre="required to accomplish such complete remissions.28 Hepatitis B and C" exact="Viral" post="caused hepatitis is one of the leading causes of"/>
  <result pre="accomplish such complete remissions.28 Hepatitis B and C Viral caused" exact="hepatitis" post="is one of the leading causes of morbidity and"/>
  <result pre="account for the majority of viral-hepatitis-related mortality, mostly attributable to" exact="cirrhosis" post="and hepatocellular carcinoma. To date, it is still a"/>
  <result pre="the majority of viral-hepatitis-related mortality, mostly attributable to cirrhosis and" exact="hepatocellular carcinoma." post="To date, it is still a challenge to achieve"/>
  <result pre="carcinoma. To date, it is still a challenge to achieve" exact="complete" post="HBV clearance or to prevent HCV relapse once directly"/>
  <result pre="for the use of ICI in patients with concomitant virus" exact="hepatitis" post="for treatment of cancer is the possible occurrence of"/>
  <result pre="ICI in patients with concomitant virus hepatitis for treatment of" exact="cancer" post="is the possible occurrence of immune-mediated hepatotoxicity, a frequent"/>
  <result pre="by ICI. This notion is particularly troublesome, as an immune-mediated" exact="hepatitis" post="may pose a significant diagnostic challenge in patients with"/>
  <result pre="may pose a significant diagnostic challenge in patients with underlying" exact="viral" post="or autoimmune hepatitis.30â€&quot;32 Pu et al33 recently published a"/>
  <result pre="a significant diagnostic challenge in patients with underlying viral or" exact="autoimmune" post="hepatitis.30â€&quot;32 Pu et al33 recently published a comprehensive review"/>
  <result pre="Pu et al33 recently published a comprehensive review on 186" exact="cancer" post="patients with concurrent HBV or HCV infection who had"/>
  <result pre="review on 186 cancer patients with concurrent HBV or HCV" exact="infection" post="who had received ICI treatment.33 About 20% of patients"/>
  <result pre="hepatic transaminases which was higher than those reported in ICI-treated" exact="cancer" post="patients without concurrent viral hepatitis.33 All grade 3 or"/>
  <result pre="higher than those reported in ICI-treated cancer patients without concurrent" exact="viral" post="hepatitis.33 All grade 3 or 4 toxicities were reversible"/>
  <result pre="necessitating a discontinuation of ICI. Importantly, no negative influence on" exact="infection" post="status was reported in patients receiving corticosteroids.33 It should"/>
  <result pre="patient population was not significantly increased when compared with ICI-treated" exact="cancer" post="patients without chronic viral hepatitis. Based on a recent"/>
  <result pre="not significantly increased when compared with ICI-treated cancer patients without" exact="chronic" post="viral hepatitis. Based on a recent publication reviewing the"/>
  <result pre="significantly increased when compared with ICI-treated cancer patients without chronic" exact="viral hepatitis." post="Based on a recent publication reviewing the available data"/>
  <result pre="reviewing the available data on the use of ICI in" exact="cancer" post="patients with hepatitis, it is recommended that all patients"/>
  <result pre="unclear for how long the prophylactic treatment should be continued." exact="Primary" post="prophylaxis should also be considered in patients with chronic"/>
  <result pre="continued. Primary prophylaxis should also be considered in patients with" exact="chronic" post="HBV infection, if not already on treatment. Liver function"/>
  <result pre="infection, if not already on treatment. Liver function tests and" exact="viral" post="load should routinely be monitored in virus positive patients.34"/>
  <result pre="T cell immunity.6 8 34 35 Similar to HBV infection," exact="chronic" post="HCV infection is also associated with increased PD-1 and"/>
  <result pre="immunity.6 8 34 35 Similar to HBV infection, chronic HCV" exact="infection" post="is also associated with increased PD-1 and TIM-3 expression"/>
  <result pre="alternatives into perspective, the application of ICI to treat therapy-resistant" exact="chronic" post="HCV infection is appealing.28 29 36 38 39 Gardiner"/>
  <result pre="perspective, the application of ICI to treat therapy-resistant chronic HCV" exact="infection" post="is appealing.28 29 36 38 39 Gardiner et al40"/>
  <result pre="in prolonged suppression of HCV replication in some patients with" exact="chronic" post="infection. Based on these encouraging results, further exploration of"/>
  <result pre="further exploration of PD-1 pathway inhibition is warranted for other" exact="chronic" post="viral diseases, possibly in combination with direct-acting antiviral regimens.40"/>
  <result pre="exploration of PD-1 pathway inhibition is warranted for other chronic" exact="viral" post="diseases, possibly in combination with direct-acting antiviral regimens.40 However,"/>
  <result pre="HBV infection, the number of clinical trials assessing ICI in" exact="chronic" post="HCV infection remain limited.36 41â€&quot;43 Taken together, ICI appears"/>
  <result pre="the number of clinical trials assessing ICI in chronic HCV" exact="infection" post="remain limited.36 41â€&quot;43 Taken together, ICI appears to be"/>
  <result pre="Taken together, ICI appears to be safe and effective in" exact="cancer" post="patients with concurrent HBV or HCV. Thus, HBV and"/>
  <result pre="patients with concurrent HBV or HCV. Thus, HBV and HCV" exact="infection" post="should not contraindicate ICI.34 35 Even though the risk"/>
  <result pre="conditions. Initial studies indicate that anti-PD-1 treatment is safe in" exact="chronic" post="HBV and HCV infection, but further trials are needed"/>
  <result pre="whether ICI can be used to gain HBV long-term remission.36" exact="Progressive multifocal leukoencephalopathy" post="Progressive multifocal leukoencephalopathy (PML) is a rare, often lethal"/>
  <result pre="can be used to gain HBV long-term remission.36 Progressive multifocal" exact="leukoencephalopathy" post="Progressive multifocal leukoencephalopathy (PML) is a rare, often lethal"/>
  <result pre="be used to gain HBV long-term remission.36 Progressive multifocal leukoencephalopathy" exact="Progressive multifocal leukoencephalopathy" post="(PML) is a rare, often lethal disease of the"/>
  <result pre="to gain HBV long-term remission.36 Progressive multifocal leukoencephalopathy Progressive multifocal" exact="leukoencephalopathy" post="(PML) is a rare, often lethal disease of the"/>
  <result pre="leukoencephalopathy Progressive multifocal leukoencephalopathy (PML) is a rare, often lethal" exact="disease" post="of the central nervous system caused by the JC"/>
  <result pre="leukoencephalopathy (PML) is a rare, often lethal disease of the" exact="central nervous system" post="caused by the JC polyomavirus (JCV).44 In general, JCV"/>
  <result pre="system caused by the JC polyomavirus (JCV).44 In general, JCV" exact="infection" post="is indolent and asymptomatic, but may become symptomatic and"/>
  <result pre="general, JCV infection is indolent and asymptomatic, but may become" exact="symptomatic" post="and fatal in immunocompromised patients, for example, patients infected"/>
  <result pre="immunosuppressive therapies.45 46 Currently, no proven therapeutic strategy for this" exact="disease" post="has been established. Based on evidence that T cell"/>
  <result pre="benefit or stabilization of PML and a decrease in JCV" exact="viral" post="load. Contrasting results were observed in another study, three"/>
  <result pre="all three patients died within 8 weeks with evidence of" exact="disease" post="progression.49 As an explanation for this adverse outcome,48 the"/>
  <result pre="lymphopenia. The authors further point out that patients with severe" exact="lymphopenia" post="also did not respond favorably to ICI treatment. Hence,"/>
  <result pre="nivolumab seems to have stimulated immune activation resulting in effective" exact="disease" post="control in the patient with a concomitant hematological malignancy.50â€&quot;52"/>
  <result pre="PML. This notion may be extrapolated to ICI treatment of" exact="cancer" post="in patients with PML. To the best of our"/>
  <result pre="for PML and PML-associated cancers. Influenza Influenza, a highly contagious" exact="respiratory" post="disease, is responsible for a significant economic burden on"/>
  <result pre="more than 645,000 influenza-associated deaths worldwide.53 54 Since patients with" exact="cancer" post="are at higher risk of influenza-associated complications, vaccination, the"/>
  <result pre="cancer are at higher risk of influenza-associated complications, vaccination, the" exact="primary" post="preventive tool against influenza, is recommended. Particularly, ICI-treated patients"/>
  <result pre="et al53 reported that the post-vaccination occurrence of the influenza" exact="syndrome" post="(fever â‰¥38Â°C and the presence of at least one"/>
  <result pre="syndrome (fever â‰¥38Â°C and the presence of at least one" exact="respiratory" post="symptom together with generalized symptoms) was significantly increased in"/>
  <result pre="together with generalized symptoms) was significantly increased in patients with" exact="cancer" post="receiving ICI. In this study, the lack of efficacy"/>
  <result pre="of ICI treatment. Moreover, the same authors reported that ICI-treated" exact="cancer" post="patients who received influenza vaccination and/or developed influenza syndrome"/>
  <result pre="ICI-treated cancer patients who received influenza vaccination and/or developed influenza" exact="syndrome" post="showed longer overall survival. The effect of immunosuppressive therapy"/>
  <result pre="effect of immunosuppressive therapy for ICI-induced irAE on the influenza" exact="syndrome" post="was not addressed in these studies.54 In rare cases,"/>
  <result pre="was not addressed in these studies.54 In rare cases, influenza" exact="infection" post="and vaccination are associated with the occurrence of organ-specific"/>
  <result pre="infection and vaccination are associated with the occurrence of organ-specific" exact="autoimmune" post="conditions, such as Guillain-BarrÃ© syndrome, a rapid onset muscle"/>
  <result pre="organ-specific autoimmune conditions, such as Guillain-BarrÃ© syndrome, a rapid onset" exact="muscle" post="weakness caused by the immune system attacking peripheral nerves."/>
  <result pre="rapid onset muscle weakness caused by the immune system attacking" exact="peripheral" post="nerves. The risk of influenza vaccine-induced Guillain-BarrÃ© syndrome is"/>
  <result pre="system attacking peripheral nerves. The risk of influenza vaccine-induced Guillain-BarrÃ©" exact="syndrome" post="is extremely small. Notably, however, Yuen et al55 reported"/>
  <result pre="Yuen et al55 reported a patient with previous post-vaccination Guillain-BarrÃ©" exact="syndrome" post="who developed a fatal reactivation following the initiation of"/>
  <result pre="results from animal experiments showing increased T cell responses to" exact="viral" post="antigens under PD-1 inhibition.56 Moreover, it has been suggested"/>
  <result pre="58 LÃ¤ubli et al59 reported a small cohort of ICI-treated" exact="cancer" post="patients that had received influenza vaccinations and subsequently experienced"/>
  <result pre="increase in incidence or severity of irAE in patients with" exact="cancer" post="on ICI who received influenza vaccinations. Twenty per cent"/>
  <result pre="vaccination was not correlated with an increased risk of subsequent" exact="myocarditis" post="among patients on ICI. Indeed, rates of vaccination were"/>
  <result pre="myocarditis among patients on ICI. Indeed, rates of vaccination were" exact="lower" post="among patients who did develop ICI-induced myocarditis, and the"/>
  <result pre="develop ICI-induced myocarditis, and the vaccination was associated with a" exact="lower" post="risk of other irAEs, in particular ICI-induced pneumonitis.65 Unfortunately,"/>
  <result pre="cases. In this context, Yu et al66 reported that influenza" exact="infection" post="substantially increases the number of highly PD-1 positive innate"/>
  <result pre="the lungs of mice. Anti-PD-1 treatment resulted in reduction of" exact="total" post="lung innate lymphoid cells with almost complete loss of"/>
  <result pre="in reduction of total lung innate lymphoid cells with almost" exact="complete" post="loss of PD-1 highly positive cells. Hence, they suggested"/>
  <result pre="that anti-PD-1 treatment may provide an effective approach for both" exact="disease" post="prevention and treatment.66 COVID-19 In March 2020, the COVID-19"/>
  <result pre="2020, the COVID-19 outbreak, which is caused by the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-COV-2), was officially proclaimed a"/>
  <result pre="the COVID-19 outbreak, which is caused by the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-COV-2), was officially proclaimed a pandemic"/>
  <result pre="COVID-19 outbreak, which is caused by the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-COV-2), was officially proclaimed a pandemic by"/>
  <result pre="in China. In 14% of confirmed cases, the course of" exact="disease" post="was severe and in 5% critical. The so-called case"/>
  <result pre="CFR usually observed in seasonal influenza (approximately 0.1%). However, current" exact="infection" post="rates as well as CFR still have to be"/>
  <result pre="still have to be considered with caution.68 Risk for severe" exact="disease" post="and death is strongly associated with older age (in"/>
  <result pre="is strongly associated with older age (in particular &amp;gt;70 years)," exact="cardiovascular disease," post="diabetes, obesity, chronic respiratory disease, hypertension, and cancer.68â€&quot;70 Laboratory"/>
  <result pre="older age (in particular &amp;gt;70 years), cardiovascular disease, diabetes, obesity," exact="chronic" post="respiratory disease, hypertension, and cancer.68â€&quot;70 Laboratory predictors for severe"/>
  <result pre="age (in particular &amp;gt;70 years), cardiovascular disease, diabetes, obesity, chronic" exact="respiratory" post="disease, hypertension, and cancer.68â€&quot;70 Laboratory predictors for severe and"/>
  <result pre="disease, hypertension, and cancer.68â€&quot;70 Laboratory predictors for severe and fatal" exact="disease" post="predominantly include elevated lactate dehydrogenase, pro-calcitonin, and D-dimers, increased"/>
  <result pre="and D-dimers, increased serum levels of cytokines IL-6, IL-10 and" exact="tumor" post="necrosis factor-Î± (TNF-Î±), as well as decreased lymphocyte counts,"/>
  <result pre="Indeed, Biao et al71 recently demonstrated that the number of" exact="total" post="T lymphocytes in the peripheral blood was significantly decreased"/>
  <result pre="demonstrated that the number of total T lymphocytes in the" exact="peripheral" post="blood was significantly decreased in patients with COVID-19. This"/>
  <result pre="in patients who needed intensive care unit (ICU) treatment. Importantly," exact="lymphopenia" post="was negatively associated with patient survival. Biao et al69â€&quot;71"/>
  <result pre="in future studies.71 Additionally, as assessed by flow cytometry of" exact="peripheral" post="blood, T cells of severely affected patients are characterized"/>
  <result pre="T cells was observed when patients progressed from prodromal to" exact="symptomatic" post="stages, indicating that T lymphocyte exhaustionâ€&quot;similar to other viral"/>
  <result pre="to symptomatic stages, indicating that T lymphocyte exhaustionâ€&quot;similar to other" exact="viral" post="infectionsâ€&quot;is a hallmark of COVID-19 as well. The expression"/>
  <result pre="of PD-1 and Tim-3) are likely to mediate T cell" exact="lymphopenia" post="in patients with COVID-19 through programmed cell death.73 To"/>
  <result pre="patients with COVID-19 through programmed cell death.73 To date, very" exact="limited" post="data are available addressing the clinical outcome of ICI-treated"/>
  <result pre="limited data are available addressing the clinical outcome of ICI-treated" exact="cancer" post="patients also suffering from COVID-19 infection.74â€&quot;77 The blockade of"/>
  <result pre="exhaustion and restore vigorous T lymphocytic cytotoxicity against both the" exact="tumor" post="and the viral antigens. However, as discussed by Chiappelli"/>
  <result pre="vigorous T lymphocytic cytotoxicity against both the tumor and the" exact="viral" post="antigens. However, as discussed by Chiappelli et al,75 this"/>
  <result pre="et al,75 this may work only at the initial and" exact="intermediate" post="stage when PD-1 expression on cytotoxic T cells ranges"/>
  <result pre="also of great significance with respect to the cytokine release" exact="syndrome" post="(CRS, â€˜cytokine stormâ€™), a phenomenon of massive inflammatory reaction,"/>
  <result pre="TNF-Î±) are rapidly produced in large amounts in response to" exact="infectious" post="agents.71 Similar to SARS-COV and the Middle East respiratory"/>
  <result pre="to infectious agents.71 Similar to SARS-COV and the Middle East" exact="respiratory" post="syndrome (MERS-COV), SARS-COV-2 is associated with increased amounts of"/>
  <result pre="infectious agents.71 Similar to SARS-COV and the Middle East respiratory" exact="syndrome" post="(MERS-COV), SARS-COV-2 is associated with increased amounts of proinflammatory"/>
  <result pre="proinflammatory cytokines in the serum, which are suspected to cause" exact="pulmonary" post="inflammation and extensive lung damage.72 However, unlike SARS-COV and"/>
  <result pre="and extensive lung damage.72 However, unlike SARS-COV and MERS-COV, SARS-COV-2" exact="infection" post="appears to be associated with the activation of both"/>
  <result pre="T helper 1 (Th-1) and Th-2 lymphocytes. SARS-COV-2 predominantly targets" exact="epithelial" post="cells of the respiratory tract, leading to severe alveolar"/>
  <result pre="and Th-2 lymphocytes. SARS-COV-2 predominantly targets epithelial cells of the" exact="respiratory" post="tract, leading to severe alveolar damage. However, COVID-19 also"/>
  <result pre="evidence for changes in the lung stroma, suggesting that also" exact="pulmonary" post="fibrosis is induced at some time point.58 Moreover, similar"/>
  <result pre="due to cross-reactivity of the induced immune reaction to both" exact="viral" post="(eg, spike surface proteins) and host protein epitopes. Lyons-Weiler58"/>
  <result pre="could pose the risk of immune overactivation and aggravation of" exact="autoimmune" post="processes. Similar to the â€˜cytokine stormâ€™ observed in patients"/>
  <result pre="Furthermore, one of the observed irAE of anti-PD-1-based ICI is" exact="autoimmune" post="pneumonitis, which may occur in up to 5% of"/>
  <result pre="to 5% of all treated patients.79â€&quot;81 Patients with non-small cell" exact="lung cancer" post="treated with ICI may even experience autoimmune pneumonitis in"/>
  <result pre="5% of all treated patients.79â€&quot;81 Patients with non-small cell lung" exact="cancer" post="treated with ICI may even experience autoimmune pneumonitis in"/>
  <result pre="non-small cell lung cancer treated with ICI may even experience" exact="autoimmune" post="pneumonitis in up to 20% of cases.81 Since the"/>
  <result pre="management. The occurrence of irAEs frequently necessitates the use of" exact="systemic" post="corticosteroids or other immunosuppressive/immunomodulating agents such as mycophenolate acid"/>
  <result pre="as mycophenolate acid or TNF-Î± blockers. Whether the use of" exact="systemic" post="corticosteroids is harmful in the setting of COVID-19 is"/>
  <result pre="glucocorticoids are one of the most frequently used adjuncts in" exact="acute" post="respiratory distress syndrome, even though the effectiveness of steroids"/>
  <result pre="are one of the most frequently used adjuncts in acute" exact="respiratory" post="distress syndrome, even though the effectiveness of steroids in"/>
  <result pre="even though the effectiveness of steroids in the management of" exact="acute" post="lung injury is ambiguous.82 This is also true for"/>
  <result pre="methylprednisolone may be one feasible approach in SARS-COV-2-related pneumonitis and" exact="respiratory" post="distress syndrome.83 Hence, possible ICI-induced irAEs could be safely"/>
  <result pre="to diminish irAEs in unresectable stage III or stage IV" exact="melanoma" post="patients (NCT03999749).84 A novel approach to ICI in cancer"/>
  <result pre="IV melanoma patients (NCT03999749).84 A novel approach to ICI in" exact="cancer" post="and viral infections, particularly COVID-19, represents CD200 checkpoint reversal.85"/>
  <result pre="patients (NCT03999749).84 A novel approach to ICI in cancer and" exact="viral" post="infections, particularly COVID-19, represents CD200 checkpoint reversal.85 The CD200"/>
  <result pre="to the use of ICI in patients with the novel" exact="infectious disease" post="COVID-19. In comparison to chemotherapeutic regimens ICI cannot be"/>
  <result pre="the use of ICI in patients with the novel infectious" exact="disease" post="COVID-19. In comparison to chemotherapeutic regimens ICI cannot be"/>
  <result pre="reported. In a meta-analysis of 9324 patients, the frequency of" exact="neutropenia" post="was smaller than 1%.88 Previously reported reactivation of viral"/>
  <result pre="of neutropenia was smaller than 1%.88 Previously reported reactivation of" exact="viral" post="infections (ie, cytomegalovirus, hepatitis B) under ICI therapy were"/>
  <result pre="neutropenia was smaller than 1%.88 Previously reported reactivation of viral" exact="infections" post="(ie, cytomegalovirus, hepatitis B) under ICI therapy were mostly"/>
  <result pre="than 1%.88 Previously reported reactivation of viral infections (ie, cytomegalovirus," exact="hepatitis" post="B) under ICI therapy were mostly observed following immunosuppressive"/>
  <result pre="at higher risk of becoming infected by SARS-COV-2 or other" exact="infectious" post="agents compared with patients without ICI treatment.76 On the"/>
  <result pre="one may assume that ICI could safely be employed in" exact="cancer" post="patients with a SARS-CoV-2 infection and even COVID-19. As"/>
  <result pre="could safely be employed in cancer patients with a SARS-CoV-2" exact="infection" post="and even COVID-19. As long as there is no"/>
  <result pre="factors discussed above, particularly with respect to how advanced the" exact="cancer" post="and/or COVID-19 are.76 79 89â€&quot;91 Quaglino et al91 recently"/>
  <result pre="89â€&quot;91 Quaglino et al91 recently reported their experience in 80" exact="melanoma" post="patients who were under ICI at the beginning of"/>
  <result pre="observations give support to the possibility of continuing ICI in" exact="melanoma" post="patients (n=80). Accordingly, Luo et al92 observed that PD-1"/>
  <result pre="tocilizumab versus standard of care in patients with advanced or" exact="metastatic" post="cancer who have COVID-19 and are not eligible to"/>
  <result pre="versus standard of care in patients with advanced or metastatic" exact="cancer" post="who have COVID-19 and are not eligible to a"/>
  <result pre="open-label, controlled, single-center pilot study, nivolumab will be employed in" exact="adult" post="patients with COVID-19 aiming to investigate the efficacy and"/>
  <result pre="investigate the efficacy and safety of nivolumab in relation to" exact="viral" post="clearance (NCT04356508). Conclusions Based on the data presented in"/>
  <result pre="in line with the recommendations of the Study Group for" exact="Infections" post="in Compromised Hosts, we assume that PD-1/PD-L1- and/or CTLA-4-based"/>
  <result pre="treatment does not seem to independently enhance the risk of" exact="infection" post="or cause more virulent course of disease.27 Hence, the"/>
  <result pre="cause more virulent course of disease.27 Hence, the above discussed" exact="viral" post="infections should not be considered as contraindications per se"/>
  <result pre="more virulent course of disease.27 Hence, the above discussed viral" exact="infections" post="should not be considered as contraindications per se for"/>
  <result pre="may increase the risk of new or reactivation of persisting" exact="viral" post="infections. Hence, physicians caring for patients receiving immunosuppressants for"/>
  <result pre="for the occurrence of symptoms or signs suggestive of new" exact="infection" post="or worsening of preexisting viral infections.27 For almost all"/>
  <result pre="or signs suggestive of new infection or worsening of preexisting" exact="viral" post="infections.27 For almost all aforementioned viral infections, there are"/>
  <result pre="or worsening of preexisting viral infections.27 For almost all aforementioned" exact="viral" post="infections, there are convincing data that disease-associated T cell"/>
  <result pre="but also a potential approach in the management of the" exact="viral infection" post="per se. Contributors: TG conceived of the review article"/>
  <result pre="also a potential approach in the management of the viral" exact="infection" post="per se. Contributors: TG conceived of the review article"/>
  <result pre="Genome Med2018;10:71. 10.1186/s13073-018-0581-y30236153 7DyckL, MillsKHGImmune checkpoints and their inhibition in" exact="cancer" post="and infectious diseases. Eur J Immunol2017;47:765â€&quot;79. 10.1002/eji.20164687528393361 8WykesMN, LewinSRImmune"/>
  <result pre="10.1186/s13073-018-0581-y30236153 7DyckL, MillsKHGImmune checkpoints and their inhibition in cancer and" exact="infectious diseases." post="Eur J Immunol2017;47:765â€&quot;79. 10.1002/eji.20164687528393361 8WykesMN, LewinSRImmune checkpoint blockade in"/>
  <result pre="diseases. Eur J Immunol2017;47:765â€&quot;79. 10.1002/eji.20164687528393361 8WykesMN, LewinSRImmune checkpoint blockade in" exact="infectious diseases." post="Nat Rev Immunol2018;18:91â€&quot;104. 10.1038/nri.2017.11228990586 9HashimotoM, KamphorstAO, ImSJ, et al.Cd8"/>
  <result pre="10.1038/nri.2017.11228990586 9HashimotoM, KamphorstAO, ImSJ, et al.Cd8 T cell exhaustion in" exact="chronic" post="infection and cancer: opportunities for interventions. Annu Rev Med2018;69:301â€&quot;18."/>
  <result pre="9HashimotoM, KamphorstAO, ImSJ, et al.Cd8 T cell exhaustion in chronic" exact="infection" post="and cancer: opportunities for interventions. Annu Rev Med2018;69:301â€&quot;18. 10.1146/annurev-med-012017-04320829414259"/>
  <result pre="PantazisN, MartinGE, et al.Exhaustion of activated CD8 T cells predicts" exact="disease" post="progression in primary HIV-1 infection. PLoS Pathog2016;12:e1005661. 10.1371/journal.ppat.100566127415828 16KaufmannDE,"/>
  <result pre="al.Exhaustion of activated CD8 T cells predicts disease progression in" exact="primary" post="HIV-1 infection. PLoS Pathog2016;12:e1005661. 10.1371/journal.ppat.100566127415828 16KaufmannDE, KavanaghDG, PereyraF, et"/>
  <result pre="al.Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with" exact="disease" post="progression and defines a reversible immune dysfunction. Nat Immunol2007;8:1246â€&quot;54."/>
  <result pre="18VeluV, ShettyRD, LarssonM, et al.Role of PD-1 co-inhibitory pathway in" exact="HIV infection" post="and potential therapeutic options. Retrovirology2015;12:14. 10.1186/s12977-015-0144-x25756928 19CookMR, KimCSafety and"/>
  <result pre="ShettyRD, LarssonM, et al.Role of PD-1 co-inhibitory pathway in HIV" exact="infection" post="and potential therapeutic options. Retrovirology2015;12:14. 10.1186/s12977-015-0144-x25756928 19CookMR, KimCSafety and"/>
  <result pre="and efficacy of immune checkpoint inhibitor therapy in patients with" exact="HIV infection" post="and advanced-stage cancer: a systematic review. JAMA Oncol2019;5:1049â€&quot;54. 10.1001/jamaoncol.2018.673730730549"/>
  <result pre="efficacy of immune checkpoint inhibitor therapy in patients with HIV" exact="infection" post="and advanced-stage cancer: a systematic review. JAMA Oncol2019;5:1049â€&quot;54. 10.1001/jamaoncol.2018.673730730549"/>
  <result pre="with expansion cohorts in HIV associated solid tumors and classical" exact="Hodgkin lymphoma" post="(cHL). JCO2018;36:TPS2597-TPS:TPS259710.1200/JCO.2018.36.15_suppl.TPS2597 23UldrickTS, IsonG, RudekMA, et al.Modernizing clinical trial"/>
  <result pre="expansion cohorts in HIV associated solid tumors and classical Hodgkin" exact="lymphoma" post="(cHL). JCO2018;36:TPS2597-TPS:TPS259710.1200/JCO.2018.36.15_suppl.TPS2597 23UldrickTS, IsonG, RudekMA, et al.Modernizing clinical trial"/>
  <result pre="RudekMA, et al.Modernizing clinical trial eligibility criteria: recommendations of the" exact="American" post="Society of clinical Oncology-Friends of cancer research HIV Working"/>
  <result pre="criteria: recommendations of the American Society of clinical Oncology-Friends of" exact="cancer" post="research HIV Working group. J Clin Oncol2017;35:3774â€&quot;80. 10.1200/JCO.2017.73.733828968173 24ColstonE,"/>
  <result pre="10.1093/infdis/jix19128431010 26LiuJ, PanW, YangDThe era of immune checkpoint therapy: from" exact="cancer" post="to viral Infection-A mini Comment on the 2018 medicine"/>
  <result pre="PanW, YangDThe era of immune checkpoint therapy: from cancer to" exact="viral" post="Infection-A mini Comment on the 2018 medicine Nobel Prize."/>
  <result pre="Sin2018;33:467â€&quot;71. 10.1007/s12250-018-0077-330570713 27Redelman-SidiG, MichielinO, CerveraC, et al.Escmid Study Group for" exact="infections" post="in compromised hosts (ESGICH) consensus document on the safety"/>
  <result pre="document on the safety of targeted and biological therapies: an" exact="infectious diseases" post="perspective (immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor"/>
  <result pre="SinnDH, KangD, et al.Incidence of extrahepatic cancers among individuals with" exact="chronic hepatitis" post="B or C virus infection: a nationwide cohort study."/>
  <result pre="KangD, et al.Incidence of extrahepatic cancers among individuals with chronic" exact="hepatitis" post="B or C virus infection: a nationwide cohort study."/>
  <result pre="B or C virus infection: a nationwide cohort study. J" exact="Viral" post="Hepat2020. 10.1111/jvh.13304. [Epub ahead of print: 27 Apr 2020]."/>
  <result pre="et al.Safety and efficacy of immune checkpoint inhibitors (ICIs) in" exact="cancer" post="patients with HIV, hepatitis B, or hepatitis C viral"/>
  <result pre="of immune checkpoint inhibitors (ICIs) in cancer patients with HIV," exact="hepatitis" post="B, or hepatitis C viral infection. J Immunother Cancer2019;7:353."/>
  <result pre="inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or" exact="hepatitis C" post="viral infection. J Immunother Cancer2019;7:353. 10.1186/s40425-019-0771-131847881 32RaoM, ValentiniD, DodooE,"/>
  <result pre="in cancer patients with HIV, hepatitis B, or hepatitis C" exact="viral infection." post="J Immunother Cancer2019;7:353. 10.1186/s40425-019-0771-131847881 32RaoM, ValentiniD, DodooE, et al.Anti-Pd-1/Pd-L1"/>
  <result pre="Immunother Cancer2019;7:353. 10.1186/s40425-019-0771-131847881 32RaoM, ValentiniD, DodooE, et al.Anti-Pd-1/Pd-L1 therapy for" exact="infectious" post="diseases: learning from the cancer paradigm. Int J Infect"/>
  <result pre="DodooE, et al.Anti-Pd-1/Pd-L1 therapy for infectious diseases: learning from the" exact="cancer" post="paradigm. Int J Infect Dis2017;56:221â€&quot;8. â€�. 10.1016/j.ijid.2017.01.02828163164 33PuD, YinL,"/>
  <result pre="and efficacy of immune checkpoint inhibitors in patients with HBV/HCV" exact="infection" post="and advanced-stage cancer: a systematic review. Medicine2020;99:e19013. 10.1097/MD.000000000001901332000444 34Tapia"/>
  <result pre="immune checkpoint inhibitors in patients with advanced cancers and pre-existing" exact="chronic" post="viral infections (hepatitis B/C, HIV): a review of the"/>
  <result pre="checkpoint inhibitors in patients with advanced cancers and pre-existing chronic" exact="viral" post="infections (hepatitis B/C, HIV): a review of the available"/>
  <result pre="inhibitors in patients with advanced cancers and pre-existing chronic viral" exact="infections" post="(hepatitis B/C, HIV): a review of the available evidence."/>
  <result pre="infections (hepatitis B/C, HIV): a review of the available evidence." exact="Cancer" post="Treat Rev2020;86:102011. 10.1016/j.ctrv.2020.10201132213376 35Pertejo-FernandezA, RicciutiB, HammondSP, et al.Safety and"/>
  <result pre="efficacy of immune checkpoint inhibitors in patients with non-small cell" exact="lung cancer" post="and hepatitis B or hepatitis C infection. Lung Cancer2020;145:S0169-5002(20)30310-X:181â€&quot;5."/>
  <result pre="of immune checkpoint inhibitors in patients with non-small cell lung" exact="cancer" post="and hepatitis B or hepatitis C infection. Lung Cancer2020;145:S0169-5002(20)30310-X:181â€&quot;5."/>
  <result pre="checkpoint inhibitors in patients with non-small cell lung cancer and" exact="hepatitis" post="B or hepatitis C infection. Lung Cancer2020;145:S0169-5002(20)30310-X:181â€&quot;5. 10.1016/j.lungcan.2020.02.013 36WielandD,"/>
  <result pre="patients with non-small cell lung cancer and hepatitis B or" exact="hepatitis C" post="infection. Lung Cancer2020;145:S0169-5002(20)30310-X:181â€&quot;5. 10.1016/j.lungcan.2020.02.013 36WielandD, HofmannM, ThimmeROvercoming CD8+ T-cell"/>
  <result pre="Lung Cancer2020;145:S0169-5002(20)30310-X:181â€&quot;5. 10.1016/j.lungcan.2020.02.013 36WielandD, HofmannM, ThimmeROvercoming CD8+ T-cell exhaustion in" exact="viral" post="hepatitis: lessons from the mouse model and clinical perspectives."/>
  <result pre="38HoogeveenRC, BoonstraACheckpoint inhibitors and therapeutic vaccines for the treatment of" exact="chronic" post="HBV infection. Front Immunol2020;11:401. 10.3389/fimmu.2020.0040132194573 39BengschB, SeigelB, RuhlM, et"/>
  <result pre="human monoclonal antibody to programmed death-1 (PD-1), in patients with" exact="chronic hepatitis C" post="virus infection. PLoS One2013;8:e63818. 10.1371/journal.pone.006381823717490 41El-KhoueiryAB, SangroB, YauT, et"/>
  <result pre="monoclonal antibody to programmed death-1 (PD-1), in patients with chronic" exact="hepatitis C" post="virus infection. PLoS One2013;8:e63818. 10.1371/journal.pone.006381823717490 41El-KhoueiryAB, SangroB, YauT, et"/>
  <result pre="to programmed death-1 (PD-1), in patients with chronic hepatitis C" exact="virus infection." post="PLoS One2013;8:e63818. 10.1371/journal.pone.006381823717490 41El-KhoueiryAB, SangroB, YauT, et al.Nivolumab in"/>
  <result pre="10.1371/journal.pone.006381823717490 41El-KhoueiryAB, SangroB, YauT, et al.Nivolumab in patients with advanced" exact="hepatocellular carcinoma" post="(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation"/>
  <result pre="41El-KhoueiryAB, SangroB, YauT, et al.Nivolumab in patients with advanced hepatocellular" exact="carcinoma" post="(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation"/>
  <result pre="with nivolumab with and without therapeutic vaccination for virally suppressed" exact="chronic hepatitis" post="B: a pilot study. J Hepatol2019;71:900â€&quot;7. 10.1016/j.jhep.2019.06.02831306680 43LiuJ, ZhangE,"/>
  <result pre="nivolumab with and without therapeutic vaccination for virally suppressed chronic" exact="hepatitis" post="B: a pilot study. J Hepatol2019;71:900â€&quot;7. 10.1016/j.jhep.2019.06.02831306680 43LiuJ, ZhangE,"/>
  <result pre="in vivo by combining therapeutic vaccination and PD-L1 blockade in" exact="chronic" post="hepadnaviral infection. PLoS Pathog2014;10:e1003856. 10.1371/journal.ppat.100385624391505 44TanCS, KoralnikIJProgressive multifocal leukoencephalopathy"/>
  <result pre="in chronic hepadnaviral infection. PLoS Pathog2014;10:e1003856. 10.1371/journal.ppat.100385624391505 44TanCS, KoralnikIJProgressive multifocal" exact="leukoencephalopathy" post="and other disorders caused by JC virus: clinical features"/>
  <result pre="Neurol2010;9:425â€&quot;37. â€�. 10.1016/S1474-4422(10)70040-520298966 45WeberT, TrebstC, FryeS, et al.Analysis of the" exact="systemic" post="and intrathecal humoral immune response in progressive multifocal leukoencephalopathy."/>
  <result pre="al.Analysis of the systemic and intrathecal humoral immune response in" exact="progressive multifocal leukoencephalopathy." post="J Infect Dis1997;176:250â€&quot;95. 10.1086/5140329207375 46KartauM, SipilÃ¤JO, AuvinenE, et al.Progressive"/>
  <result pre="J Med2019;380:1667â€&quot;8. 10.1056/NEJMe190414030969502 48CorteseI, MuranskiP, Enose-AkahataY, et al.Pembrolizumab treatment for" exact="progressive multifocal leukoencephalopathy." post="N Engl J Med2019;380:1597â€&quot;605. 10.1056/NEJMoa181503930969503 49MedranoC, VergezF, MengelleC, et"/>
  <result pre="et al.Effectiveness of immune checkpoint inhibitors in transplant recipients with" exact="progressive multifocal leukoencephalopathy." post="Emerg Infect Dis2019;25:2145â€&quot;7. 10.3201/eid2511.19070531625858 50HoangE, BartlettNL, GoyalMS, et al.Progressive"/>
  <result pre="Emerg Infect Dis2019;25:2145â€&quot;7. 10.3201/eid2511.19070531625858 50HoangE, BartlettNL, GoyalMS, et al.Progressive multifocal" exact="leukoencephalopathy" post="treated with nivolumab. J Neurovirol2019;25:284â€&quot;7. 10.1007/s13365-019-00738-x30864100 51Audemard-VergerA, GasnaultJ, FaisantM,"/>
  <result pre="et al.Sustained response and rationale of programmed cell Death-1-Targeting for" exact="progressive multifocal leukoencephalopathy." post="Open Forum Infect Dis2019;6:ofz374. 10.1093/ofid/ofz37431660340 52TanCS, BordE, BrogeTA, et"/>
  <result pre="program cell death-1 expression on T lymphocytes of patients with" exact="progressive multifocal leukoencephalopathy." post="J Acquir Immune Defic Syndr2012;60:244â€&quot;8. 10.1097/QAI.0b013e31825a313c22549384 53BersanelliM, GiannarelliD, CastrignanÃ²P,"/>
  <result pre="et al.State of the art about influenza vaccination for advanced" exact="cancer" post="patients receiving immune checkpoint inhibitors: when common sense is"/>
  <result pre="10.1016/j.critrevonc.2019.05.00331112887 55YuenC, KamsonD, SolivenB, et al.Severe relapse of vaccine-induced Guillain-BarrÃ©" exact="syndrome" post="after treatment with nivolumab. J Clin Neuromuscul Dis2019;20:194â€&quot;9. 10.1097/CND.000000000000023031135622"/>
  <result pre="TangA, LiF, et al.Pd-1 blockade in rhesus macaques: impact on" exact="chronic" post="infection and prophylactic vaccination. J Immunol2009;182:980â€&quot;7. 10.4049/jimmunol.182.2.98019124741 57ChongCR, ParkVJ,"/>
  <result pre="LiF, et al.Pd-1 blockade in rhesus macaques: impact on chronic" exact="infection" post="and prophylactic vaccination. J Immunol2009;182:980â€&quot;7. 10.4049/jimmunol.182.2.98019124741 57ChongCR, ParkVJ, CohenB,"/>
  <result pre="57ChongCR, ParkVJ, CohenB, et al.Safety of inactivated influenza vaccine in" exact="cancer" post="patients receiving immune checkpoint inhibitors. Clin Infect Dis2020;70:193â€&quot;9. 10.1093/cid/ciz20230874791"/>
  <result pre="Transl Autoimmun2020;3:100051. 10.1016/j.jtauto.2020.100051 59LÃ¤ubliH, BalmelliC, KaufmannL, et al.Influenza vaccination of" exact="cancer" post="patients during PD-1 blockade induces serological protection but may"/>
  <result pre="DeRemerDL, SaundersKM, et al.Immune-Mediated adverse events following influenza vaccine in" exact="cancer" post="patients receiving immune checkpoint inhibitors. J Oncol Pharm Pract2020;26:647â€&quot;54."/>
  <result pre="10.1177/107815521986875831474214 61WijnDH, GroeneveldGH, VollaardAM, et al.Influenza vaccination in patients with" exact="lung cancer" post="receiving anti-programmed death receptor 1 immunotherapy does not induce"/>
  <result pre="61WijnDH, GroeneveldGH, VollaardAM, et al.Influenza vaccination in patients with lung" exact="cancer" post="receiving anti-programmed death receptor 1 immunotherapy does not induce"/>
  <result pre="HoTP, YadavS, et al.Safety of influenza vaccine in patients with" exact="cancer" post="receiving pembrolizumab. JCO Oncol Pract2020;6:JOP1900495:JOP.19.00495. 10.1200/JOP.19.00495 63GroeneveldGH, WijnDH, VollaardAMImmune-Related"/>
  <result pre="Pract2020;6:JOP1900495:JOP.19.00495. 10.1200/JOP.19.00495 63GroeneveldGH, WijnDH, VollaardAMImmune-Related adverse events in patients with" exact="cancer" post="receiving influenza vaccination and immune checkpoint inhibitors. Clin Infect"/>
  <result pre="KangCK, JunKI, et al.Immunogenicity of influenza vaccination in patients with" exact="cancer" post="receiving immune checkpoint inhibitor. Clin Infect Dis2019:pii: ciz1092. 10.1093/cid/ciz1092"/>
  <result pre="Dis2019:pii: ciz1092. 10.1093/cid/ciz1092 65AwadallaM, GoldenDLA, MahmoodSS, et al.Influenza vaccination and" exact="myocarditis" post="among patients receiving immune checkpoint inhibitors. J Immunother Cancer2019;7:53."/>
  <result pre="26 Apr 2020]. 68JordanRE, AdabP, ChengKKCovid-19: risk factors for severe" exact="disease" post="and death. BMJ2020;368:m1198. 10.1136/bmj.m119832217618 69ZhouF, YuT, DuR, et al.Clinical"/>
  <result pre="DuR, et al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="XuS, YuM, et al.Risk factors for severity and mortality in" exact="adult" post="COVID-19 inpatients in Wuhan. J Allergy Clin Immunol2020;pii: S0091-6749:30495â€&quot;4."/>
  <result pre="and functional exhaustion of T cells in patients with coronavirus" exact="disease" post="2019 (COVID-19). Front Immunol2020;11:827. 10.3389/fimmu.2020.0082732425950 72HuangC, WangY, LiX, et"/>
  <result pre="fatal evolution of coronavirus Disease-19 in a patient with advanced" exact="lung cancer" post="with a long-time response to nivolumab. J Thorac Oncol2020;15:e83â€&quot;5."/>
  <result pre="evolution of coronavirus Disease-19 in a patient with advanced lung" exact="cancer" post="with a long-time response to nivolumab. J Thorac Oncol2020;15:e83â€&quot;5."/>
  <result pre="et al.State of the art about influenza vaccination for advanced" exact="cancer" post="patients receiving immune checkpoint inhibitors: when common sense is"/>
  <result pre="Oncol Hematol2019;139:87â€&quot;90. 10.1016/j.critrevonc.2019.05.00331112887 76KattanJ, KattanC, AssiTDo checkpoint inhibitors compromise the" exact="cancer" post="patients' immunity and increase the vulnerability to COVID-19 infection?Immunotherapy2020;12:351â€&quot;4."/>
  <result pre="IbrahimN, et al.What the oncologist needs to know about COVID-19" exact="infection" post="in cancer patients. Future Oncol2020;16:1153â€&quot;6. 10.2217/fon-2020-031232323577 78AgrawalAS, TaoX, AlgaissiA,"/>
  <result pre="al.What the oncologist needs to know about COVID-19 infection in" exact="cancer" post="patients. Future Oncol2020;16:1153â€&quot;6. 10.2217/fon-2020-031232323577 78AgrawalAS, TaoX, AlgaissiA, et al.Immunization"/>
  <result pre="10.2217/fon-2020-031232323577 78AgrawalAS, TaoX, AlgaissiA, et al.Immunization with inactivated middle East" exact="respiratory" post="syndrome coronavirus vaccine leads to lung immunopathology on challenge"/>
  <result pre="78AgrawalAS, TaoX, AlgaissiA, et al.Immunization with inactivated middle East respiratory" exact="syndrome" post="coronavirus vaccine leads to lung immunopathology on challenge with"/>
  <result pre="checkpoint inhibitors. Immunotherapy2020;12:imt-2020-006710.2217/imt-2020-006732212881 80RotzSJ, LeinoD, SzaboS, et al.Severe cytokine release" exact="syndrome" post="in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer2017;64:e2664210.1002/pbc.26642"/>
  <result pre="cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr" exact="Blood" post="Cancer2017;64:e2664210.1002/pbc.26642 81SureshK, VoongKR, ShankarB, et al.Pneumonitis in non-small cell"/>
  <result pre="Blood Cancer2017;64:e2664210.1002/pbc.26642 81SureshK, VoongKR, ShankarB, et al.Pneumonitis in non-small cell" exact="lung cancer" post="patients receiving immune checkpoint immunotherapy: incidence and risk factors."/>
  <result pre="Cancer2017;64:e2664210.1002/pbc.26642 81SureshK, VoongKR, ShankarB, et al.Pneumonitis in non-small cell lung" exact="cancer" post="patients receiving immune checkpoint immunotherapy: incidence and risk factors."/>
  <result pre="et al.Effectiveness of glucocorticoid therapy in patients with severe coronavirus" exact="disease" post="2019: protocol of a randomized controlled trial. Chin Med"/>
  <result pre="UrbaWJ, et al.Insights from immuno-oncology: the Society for immunotherapy of" exact="cancer" post="statement on access to IL-6-targeting therapies for COVID-19. J"/>
  <result pre="et al.Cd200 checkpoint reversal: a novel approach to immunotherapy. Clin" exact="Cancer" post="Res2020;26:232â€&quot;41. 10.1158/1078-0432.CCR-19-223431624103 86CeribelliA, MottaF, De SantisM, et al.Recommendations for"/>
  <result pre="Res2020;26:232â€&quot;41. 10.1158/1078-0432.CCR-19-223431624103 86CeribelliA, MottaF, De SantisM, et al.Recommendations for coronavirus" exact="infection" post="in rheumatic diseases treated with biologic therapy. J Autoimmun2020;109:102442."/>
  <result pre="86CeribelliA, MottaF, De SantisM, et al.Recommendations for coronavirus infection in" exact="rheumatic" post="diseases treated with biologic therapy. J Autoimmun2020;109:102442. 10.1016/j.jaut.2020.10244232253068 87KarnamG,"/>
  <result pre="RygielTP, RaabenM, et al.Cd200 receptor controls sex-specific TLR7 responses to" exact="viral infection." post="PLoS Pathog2012;8:e1002710. 10.1371/journal.ppat.100271022615569 88ZhuangJ, DuJ, GuoX, et al.Clinical diagnosis"/>
  <result pre="89DavisAP, BoyerM, LeeJH, et al.COVID-19: the use of immunotherapy in" exact="metastatic" post="lung cancer. Immunotherapy2020;12:545â€&quot;8. 10.2217/imt-2020-009632349579 90VardhanaSA, WolchokJDThe many faces of"/>
  <result pre="BoyerM, LeeJH, et al.COVID-19: the use of immunotherapy in metastatic" exact="lung cancer." post="Immunotherapy2020;12:545â€&quot;8. 10.2217/imt-2020-009632349579 90VardhanaSA, WolchokJDThe many faces of the anti-COVID"/>
  <result pre="J Exp Med2020;217:pii: e20200678. 10.1084/jem.20200678 91QuaglinoP, FavaP, BrizioM, et al.Metastatic" exact="melanoma" post="treatment with checkpoint inhibitors in the COVIDâ€�19 era: experience"/>
  <result pre="checkpoint inhibitors in the COVIDâ€�19 era: experience from an Italian" exact="skin cancer" post="unit. J Eur Acad Dermatol Venereol2020;3810.1111/jdv.16586 92LuoJ, RizviH, EggerJV,"/>
  <result pre="inhibitors in the COVIDâ€�19 era: experience from an Italian skin" exact="cancer" post="unit. J Eur Acad Dermatol Venereol2020;3810.1111/jdv.16586 92LuoJ, RizviH, EggerJV,"/>
  <result pre="blockade on severity of COVID-19 in patients with lung cancers." exact="Cancer" post="Discov2020:CD-20-0596. 10.1158/2159-8290.CD-20-0596 93BonamSR, KaveriSV, SakuntabhaiA, et al.Adjunct immunotherapies for"/>
 </snippets>
</snippetsTree>
